Back
Protagonist Therapeutics 10K Form
Sell
41
PTGX
Protagonist Therapeutics
Last Price:
$38.95
Seasonality Move:
14.14%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-02 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2023-08-03 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2023-05-04 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2022-11-08 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2022-08-04 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2022-05-05 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
Receive PTGX News And Ratings
See the #1 stock for the next 7 days that we like better than PTGX
PTGX Financial Statistics
Sales & Book Value
| Annual Sales: | $60M |
|---|---|
| Cash Flow: | $-28.6M |
| Price / Cash Flow: | 10.5 |
| Annual Sales: | $8.94 |
| Price / Book: | 4.37 |
Profitability
| EPS (TTM): | 2.66000 |
|---|---|
| Net Income (TTM): | $170.8M |
| Gross Margin: | -- |
| Return on Equity: | 37.59% |
| Return on Assets: | 33.69% |
Protagonist Therapeutics Earnings Forecast
Key Protagonist Therapeutics Financial Ratios
-
The Research & Development expenses have been 200.27% of Revenue.
-
The Interest Expense is 0.00% of Operating Income.
-
The Net Earning history of PTGX is -131.59% of Total Revenues.
-
Per Share Earnings over the last 10 years have been positive in 5 years.
Protagonist Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | PTGX |
| CUSIP: | 74366E |
| Website: | protagonist-inc.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 10.7 |
| Quick Ratio: | 10.57 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
PTGX Technical Analysis vs Fundamental Analysis
Sell
41
Protagonist Therapeutics (PTGX)
is a Sell
Is Protagonist Therapeutics a Buy or a Sell?
-
Protagonist Therapeutics stock is rated a SellThe current Protagonist Therapeutics [PTGX] share price is $38.96. The Score for PTGX is 41, which is 18% below its historic median score of 50, and infers higher risk than normal.